EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis

Steven J Edwards iD, Charlotta Karner iD, Tracey Jhita iD, Samantha Barton iD, Gemma Marceniuk iD, Zenas Z N Yiu iD, Miriam Wittmann iD

Health Technology Assessment · 2024

DOI: 10.3310/lexb9006 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2024. Verfasst von Steven J Edwards und 6 weiteren Autor:innen. Beteiligte Einrichtung: Director of Health Technology Assessment, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Cost-Benefit Analysis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis is a chronic relapsing inflammatory skin condition. One of the most common skin disorders in children, atopic dermatitis typically manifests before the age of 5 years, but it can develop at any age. Atopic dermatitis is characterised by dry, inflamed skin accompanied by intense itchiness (pruritus).

Objectives

To appraise the clinical and cost effectiveness of abrocitinib, tralokinumab and upadacitinib within their marketing authorisations as alternative therapies for treating moderate-to-severe atopic dermatitis compared to systemic immunosuppressants (first-line ciclosporin A or second-line dupilumab and baricitinib). Data sources Studies were identified from an existing systematic review (search date 2019) and update searches of electronic databases (MEDLINE, EMBASE, CENTRAL) to November 2021, from bibliographies of retrieved studies, clinical trial registers and evidence provided by the sponsoring companies of the treatments under review.

Methods

A systematic review of the clinical effectiveness literature was carried out and a network meta-analysis undertaken for adults and adolescents at different steps of the treatment pathway. The primary outcome of interest was a combined response of Eczema Area and Severity Index 50 + Dermatology Life Quality Index ≥ 4; where this was consistently unavailable for a step in the pathway, an analysis of Eczema Area and Severity Index 75 was conducted. A de novo economic model was developed to assess cost effectiveness from the perspective of the National Health Service in England. The model structure was informed through systematic review of the economic literature and by consulting clinical experts. Effectiveness data were obtained from the network meta-analysis. Costs and utilities were obtained from the evidence provided by sponsoring companies and standard UK sources.

Results

Network meta-analyses indicate that abrocitinib 200 mg and upadacitinib 30 mg may be more effective, and tralokinumab may be less effective than dupilumab and baricitinib as second-line systemic therapies. Abrocitinib 100 mg and upadacitinib 15 mg have a more similar effectiveness to dupilumab. Upadacitinib 30 and 15 mg are likely to be more effective than ciclosporin A as a first-line therapy. Upadacitinib 15 mg, abrocitinib 200 and 100 mg may be more effective than dupilumab in adolescents. The cost effectiveness of abrocitinib and upadacitinib for both doses is dependent on the subgroup of interest. Tralokinumab can be considered cost-effective as a second-line systemic therapy owing to greater cost savings per quality-adjusted life-year lost.

Conclusions

The primary strength of the analysis of the three new drugs compared with current practice for each of the subpopulations is the consistent approach to the assessment of clinical and cost effectiveness. However, the conclusions are limited by the high uncertainty around the clinical effectiveness and lack of data for the primary outcome for comparisons with baricitinib and for the adolescent and adult first-line populations. Future work and limitations The most significant limitation that Eczema Area and Severity Index 50 + Dermatology Life Quality Index ≥ 4 could not be obtained for the adolescent and adult first-line systemic treatment populations is due to a paucity of data for dupilumab and ciclosporin A. A comparison of the new drugs against one another in addition to current practice would be beneficial to provide a robust view on which treatments are the most cost-effective. Study registration This study is registered as PROSPERO CRD42021266219. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: 135138) and is published in full in Health Technology Assessment ; Vol. 28, No. 4. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedCost-Benefit AnalysisHumansPyrimidinesHeterocyclic Compounds, 3-RingQuality-Adjusted Life YearsSeverity of Illness IndexAdolescentDermatologic AgentsAntibodies, MonoclonalAdultImmunosuppressive AgentsSulfonamidesAzetidinesPurinesPyrazoles

Stichwörter der Autor:innen

ABROCITINIBATOPIC DERMATITISATOPIC DERMATITISCOST EFFECTIVENESSSYSTEMATIC REVIEWCOST EFFECTIVENESSTRALOKINUMABTRALOKINUMABUPADACITINIB

Substanzen

upadacitinibabrocitinibAntibodies, Monoclonal, HumanizedtralokinumabPyrimidinesHeterocyclic Compounds, 3-RingDermatologic AgentsAntibodies, MonoclonalImmunosuppressive AgentsSulfonamides

Autor:innen und Institutionen

  • Director of Health Technology Assessment, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK.
  • Clinical Evidence Manager, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK.
  • Health Economics Manager, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK.
  • Principal Clinical Evidence Analyst, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK.
  • Senior Health Economist, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK.
  • NIHR Clinical Lecturer in Dermatology, University of Manchester, Manchester, UK.

ORCID-Profile: Steven J Edwards, Charlotta Karner, Tracey Jhita, Samantha Barton, Gemma Marceniuk, Zenas Z N Yiu, Miriam Wittmann

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Edwards, S. J., Karner, C., Jhita, T., Barton, S., Marceniuk, G., Yiu, Z. Z. N., & Wittmann, M. (2024). Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. Health Technology Assessment. https://doi.org/10.3310/lexb9006

Vancouver

Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, Yiu ZZN, et al. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. Health Technology Assessment. 2024. doi:10.3310/lexb9006

BibTeX
@article{Edwards2024,
  author = {Edwards, Steven J and Karner, Charlotta and Jhita, Tracey and Barton, Samantha and Marceniuk, Gemma and Yiu, Zenas Z N and Wittmann, Miriam},
  title = {Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis},
  journal = {Health Technology Assessment},
  year = {2024},
  doi = {10.3310/lexb9006}
}
Kostenlos starten →